This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Aldafermin
- DrugBank Accession Number
- DB16086
- Background
Aldafermin is under investigation in clinical trial NCT03912532 (Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study in Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)).
- Type
- Biotech
- Groups
- Investigational
- Synonyms
- (phe5>met,ser6>arg,ala8>ser,gly9>ser,his11>leu) fibroblast growth factor 19 (human fgf19) (5-194)-peptide, produced in escherichia coli
- Aldafermin
- Engineered variant of recombinant human fibroblast growth factor 19
- External IDs
- NGM-282
- NGM282
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- IK9NYN31ZM
- CAS number
- 1616639-03-2
References
- General References
- Not Available
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Bile Acid Diarrhea / Bile Acid Malabsorption Syndrome Type II / Bileacid Malabsorption / Chronic Diarrhea / Diarrhoea Predominant Irritable Bowel Syndrome / Functional Diarrhea 1 2 Completed Treatment Compensated liver disease / Non Alcoholic Steatohepatitis (NASH) 1 2 Completed Treatment Diabetes Mellitus 1 2 Completed Treatment Non Alcoholic Steatohepatitis (NASH) 2 2 Completed Treatment Primary Biliary Cholangitis 2 2 Completed Treatment Primary Sclerosing Cholangitis (PSC) 1 1 Completed Treatment Diabetes Mellitus 1 1 Completed Treatment Healthy, Male 1 1 Completed Treatment Impaired Hepatic Function 1 1 Completed Treatment Impaired Renal Function 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at December 15, 2020 18:04 / Updated at February 21, 2021 18:55